• Pinar Özdemir Akdur and Nazan Çiledağ.
• SBU Dr. Abdurahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Radiology, Ankara, Turkey.
• Medicine (Baltimore). 2023 Oct 27; 102 (43): e35798e35798.

AbstractIn this study, we investigated the molecular phenotype-cancer relationship that may favor the main metastatic tendencies of cancer by comparing the association of receptor subtypes with the presence of metastasis, serosal metastasis, and/or visceral metastases in patients diagnosed with breast cancer. In this study, we retrospectively evaluated 853 patients who were diagnosed with breast cancer and followed up at our hospital between 2017 and 2022. The probability of metastasis in the most common tumor group, the non-special type of invasive carcinoma was significantly higher than that in other tumor groups. We formed our groups according to estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 status. In addition, when we compared the receptor groups, no significant difference was found between the receptor groups (Table 1). When the entire breast cancer cohort was considered, the association of serosal metastasis was statistically significantly higher in the ER and/or PR (+) and, HER2 (-) receptor subgroup than in all other receptor groups (P < .006), and the association of visceral metastasis/visceral + serosal metastasis with the ER and/or PR (+) and, HER2 (-) receptor subgroup was significantly higher than that in all other receptor groups (P < .001) (Table 2). In this study, we aimed to investigate the possible relationship between molecular markers of the primary tumor and the preference for serosal and visceral metastases over distant metastases in a large cohort of patients to contribute to the improvement of the diagnosis and treatment of breast cancer, a heterogeneous disease group. To the best of our knowledge, our study is the first to statistically investigate the association between receptor subgroups and visceral, serosal, and serosal + visceral metastases as a group and to reach some conclusions.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

30 keywords...

hide…